1. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. (1st August 2020) Authors: Simpson, E.L.; Lacour, J.‐P.; Spelman, L.; Galimberti, R.; Eichenfield, L.F.; Bissonnette, R.; King, B.A.; Thyssen, J.P.; Silverberg, J.I.; Bieber, T.; Kabashima, K.; Tsunemi, Y.; Costanzo, A.; Guttman‐Yassky, E.; Beck, L.A.; Janes, J.M.; DeLozier, A.M.; Gamalo, M.; Brinker, D.R.; Cardillo, T. Journal: British journal of dermatology Issue: Volume 183:Number 2(2020) Page Start: 242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. (5th March 2020) Authors: Simpson, E.L.; Lacour, J.‐P.; Spelman, L.; Galimberti, R.; Eichenfield, L.F.; Bissonnette, R.; King, B.A.; Thyssen, J.P.; Silverberg, J.I.; Bieber, T.; Kabashima, K.; Tsunemi, Y.; Costanzo, A.; Guttman‐Yassky, E.; Beck, L.A.; Janes, J.M.; DeLozier, A.M.; Gamalo, M.; Brinker, D.R.; Cardillo, T. Journal: British journal of dermatology Issue: Volume 183:Number 2(2020) Page Start: 242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗